A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Mar 11

PMID 36902608

Authors

Xiaokaiti Naiyila

Jinze Li

Yin Huang

Bo Chen

Mengli Zhu

Jin Li

Zeyu Chen

Lu Yang

Jianzhong Ai

Qiang Wei

Liangren Liu

Dehong Cao

Affiliations

Soon will be listed here.

Abstract

Benign prostatic hyperplasia (BPH) is a common male condition that impacts many men's quality of life by generating lower urinary tract symptoms (LUTS). In recent years, inflammation has become very common in the prostate, and BPH with inflammation has a higher International Prostate Symptom Score (IPSS) score and an enlarged prostate. Chronic inflammation leads to tissue damage and the release of pro-inflammatory cytokines, which play an important role in the pathogenesis of BPH. We will focus on current advancements in pro-inflammatory cytokines in BPH, as well as the future of pro-inflammatory cytokine research.

Citing Articles

Standardized Leaf Extract Exhibited Antiproliferative Activity Against TGF-β-induced Prostate Stromal Cells (WPMY-1) Through G 1 Phase Cell Cycle Arrest SMAD2/3 and ERK1/2 Signaling Pathways.

Kanphet Y, Uttarawichien T, Vongsak B, Boonsom T, Nalinratana N, Sivaji S In Vivo. 2025; 39(2):778-794.

PMID: 40011003 PMC: 11884491. DOI: 10.21873/invivo.13882.

Purple corn extract improves benign prostatic hyperplasia by inhibiting 5 alpha-reductase type 2 and inflammation in testosterone propionate-induced rats.

Kim S, Choi A, Lee H, Lee J, Park S, Kim B Front Pharmacol. 2025; 15():1485072.

PMID: 39830338 PMC: 11739163. DOI: 10.3389/fphar.2024.1485072.

miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.

Salgado-Hernandez S, Martinez-Retamoza L, Ocadiz-Delgado R, Perez-Mora S, Cedeno-Arboleda G, Gomez-Garcia M Cancers (Basel). 2025; 17(1.

PMID: 39796656 PMC: 11718816. DOI: 10.3390/cancers17010026.

Wang Y, Wang J, Liu J, Zhu H Front Immunol. 2024; 15:1516362.

PMID: 39703506 PMC: 11655502. DOI: 10.3389/fimmu.2024.1516362.

Anti-Inflammatory Potential of Bark Extract: An In Vitro Study of Cytokine Release by Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells.

Villar A, Silva-Fuentes F, Mula A, Zangara A Int J Mol Sci. 2024; 25(15).

PMID: 39125867 PMC: 11311769. DOI: 10.3390/ijms25158298.

References

Bostwick D, de la Roza G, Dundore P, Corica F, Iczkowski K . Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate. 2003; 55(3):187-93. DOI: 10.1002/pros.10224. View

Li J, Li Y, Cao D, Huang Y, Peng L, Meng C . The association between histological prostatitis and benign prostatic hyperplasia: a single-center retrospective study. Aging Male. 2022; 25(1):88-93. DOI: 10.1080/13685538.2022.2050360. View

Buck A . Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004; 172(5 Pt 1):1792-9. DOI: 10.1097/01.ju.0000140503.11467.8e. View

Tsai Y, Tong Y, Cheng J, Lee C, Yang F, Lee H . Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. Urol Int. 2006; 77(3):269-74. DOI: 10.1159/000094821. View

Pappu R, Ramirez-Carrozzi V, Sambandam A . The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 2011; 134(1):8-16. PMC: 3173690. DOI: 10.1111/j.1365-2567.2011.03465.x. View

Xu D, Wang X, Jiang C, Ruan Y, Xia S, Wang X . The androgen receptor plays different roles in macrophage-induced proliferation in prostate stromal cells between transitional and peripheral zones of benign prostatic hypertrophy. EXCLI J. 2017; 16:939-948. PMC: 5500834. DOI: 10.17179/excli2017-335. View

Roehrborn C . Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008; 20 Suppl 3:S11-8. DOI: 10.1038/ijir.2008.55. View

Gao R, Liu Q, Zhou H, Cao L, Jiang T, Tang S . [Expressions of interleukin-17 and interleukin-8 in the prostatic tissue of the patients with BPH or BPH with inflammation]. Zhonghua Nan Ke Xue. 2018; 23(8):697-702. View

Moreira D, Nickel J, Gerber L, Muller R, Andriole G, Castro-Santamaria R . Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study. Cancer Prev Res (Phila). 2015; 8(4):312-7. DOI: 10.1158/1940-6207.CAPR-14-0260. View

10.

De Marzo A, Platz E, Sutcliffe S, Xu J, Gronberg H, Drake C . Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7(4):256-69. PMC: 3552388. DOI: 10.1038/nrc2090. View

11.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

12.

Novara G, Giannarini G, Alcaraz A, Cozar-Olmo J, Descazeaud A, Montorsi F . Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus. 2017; 2(5):553-561. DOI: 10.1016/j.euf.2016.04.002. View

13.

Jin S, Xiang P, Liu J, Yang Y, Hu S, Sheng J . Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 T cells in benign prostatic hyperplasia. Prostate. 2019; 79(8):909-919. PMC: 6593656. DOI: 10.1002/pros.23801. View

14.

Vela-Navarrete R, Escribano-Burgos M, Farre A, Garcia-Cardoso J, Manzarbeitia F, Carrasco C . Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol. 2005; 173(2):507-10. DOI: 10.1097/01.ju.0000150533.94952.25. View

15.

Kahokehr A, Vather R, Nixon A, Hill A . Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013; 111(2):304-11. DOI: 10.1111/j.1464-410X.2012.11559.x. View

16.

Sasagawa I, Nakada T, Kazama T, Satomi S, Terada T, Katayama T . Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. Int Urol Nephrol. 1990; 22(3):279-84. DOI: 10.1007/BF02550407. View

17.

Jonler M, Riehmann M, Brinkmann R, Bruskewitz R . Benign prostatic hyperplasia. Endocrinol Metab Clin North Am. 1994; 23(4):795-807. View

18.

Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T . Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012; 110(6 Pt B):E301-7. DOI: 10.1111/j.1464-410X.2012.11144.x. View

19.

Royuela M, De Miguel M, Ruiz A, Fraile B, Arenas M, Romo E . Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw. 2000; 11(1):119-27. View

20.

Untergasser G, Madersbacher S, Berger P . Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005; 40(3):121-8. DOI: 10.1016/j.exger.2004.12.008. View